Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?
Answer from: at Community Practice
Immunotherapy has largely supplanted hedgehog inhibitors for most BCC patients given the toxicity of hedgehog inhibitors and the reliable recurrences seen after initial responses. If I want short term palliative care, I think hedgehog. If I want a real chance at a cure, I think immunotherapy.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I do not think so. I switch progressing people to immunotherapy - PD1 inhibitor, preferably on a clinical trial or off label. Cemiplimab phase 2 study for basal cell carcinoma has completed enrollment. I was impressed by the patient response I observed, but we need to wait for the final results.